Formulations of guanylate cyclase C agonists and methods of use
US9616097B2 · kind B2 · utility
3Cited by
27References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 15, 2012 |
| Grant date | Apr 11, 2017 |
| Priority date | — |
| Expiry date | Dec 31, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K7/64
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.